Gavilimomab
Source: Wikipedia, the free encyclopedia.
Monoclonal antibody
CD147 | |
|---|---|
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
 N Y (what is this?) (verify) | |
Gavilimomab (also known as ABX-CBL) is a
antithymocyte globulin therapy.[2]
It was originally developed by
.References
- ^ a b "Gavilimomab". Adis Insight. Springer Nature Switzerland AG.
- PMID 17110457.
| Intracellular (initiation) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
drug article is a stub. You can help Wikipedia by expanding it. |